Skip to main content

Table 3 Relative risk of all SMs or hematologic SMs for RAI therapy by different stratification

From: Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

 

All cancer combined

Hematologic SMs

Stratified by diagnosed age

RR(95%CI)

P value

RR(95%CI)

P value

  < 45 yrs

1.05(0.92–1.21)

0.454

2.17(1.08–4.38)

0.035

 45-59 yrs

1.08(0.99–1.19)

0.094

1.50(1.06–2.10)

0.02

 60-74 yrs

1.17(1.05–1.30)

0.004

1.70(1.29–2.25)

0.000

  > =75 yrs

1.18(0.96–1.46)

0.123

1.04(0.69–1.58)

0.832

Stratified by gender

 female

1.01(0.94–1.08)

0.816

1.31(1.05–1.64)

0.016

 male

0.94(0.85–1.05)

0.303

1.04(0.76–1.41)

0.814

Stratified by latency time

  < 5 yrs

1.11(1.01–1.22)

0.025

1.83(1.14–2.94)

0.012

 5-10 yrs

1.03(0.94–1.13)

0.536

1.13(0.85–1.50)

0.413

 10-15 yrs

0.88(0.76–1.02)

0.086

1.19(0.88–1.62)

0.266

  > =15 yrs

0.75(0.43–1.33)

0.325

0.97(0.56–1.67)

0.898